Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Published:2017-09 Issue:6 Volume:170 Page:1109-1119.e10
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Ribas Antoni,Dummer Reinhard,Puzanov Igor,VanderWalde Ari,Andtbacka Robert H.I.,Michielin Olivier,Olszanski Anthony J.,Malvehy Josep,Cebon Jonathan,Fernandez Eugenio,Kirkwood John M.,Gajewski Thomas F.,Chen Lisa,Gorski Kevin S.,Anderson Abraham A.,Diede Scott J.,Lassman Michael E.,Gansert Jennifer,Hodi F. Stephen,Long Georgina V.

Funder

NIH

Australian NHMRC fellowship

Medical Foundation K8625, University of Sydney

Amgen Inc

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference25 articles.

1. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma;Andtbacka;J. Clin. Oncol.,2015

2. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial;Andtbacka;Ann. Surg. Oncol.,2016

3. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade;Chen;Cancer Discov.,2016

4. Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB- IV melanoma;Chesney;Ann. Oncol.,2016

5. Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma;Chesney;J. Clin. Oncol.,2017

Cited by 1108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and research progress of oncolytic virus;Pharmaceutical Science Advances;2024-12

2. NK cell-based immunotherapy in hepatocellular carcinoma: An attractive therapeutic option for the next decade;Cellular Signalling;2024-12

3. A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors;Radiotherapy and Oncology;2024-11

4. Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration;Biomedicine & Pharmacotherapy;2024-10

5. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer;Biomedicine & Pharmacotherapy;2024-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3